Patents by Inventor W. Ian Lipkin
W. Ian Lipkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11583579Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: GrantFiled: March 5, 2021Date of Patent: February 21, 2023Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, RAMOT AT TEL-AVIV UNIVERSITY LTD., KIMRON VETERINARY INSTITUTEInventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20210205437Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: ApplicationFiled: March 5, 2021Publication date: July 8, 2021Inventors: W. Ian LIPKIN, Thomas BRIESE, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Patent number: 10973902Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: GrantFiled: February 6, 2020Date of Patent: April 13, 2021Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, RAMOT AT TEL-AVIV UNIVERSITY LTD., KIMRON VETERINARY INSTITUTEInventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20200254084Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: ApplicationFiled: February 6, 2020Publication date: August 13, 2020Inventors: W. Ian LIPKIN, Thomas BRIESE, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Patent number: 10596249Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: GrantFiled: August 23, 2018Date of Patent: March 24, 2020Assignees: KIMRON VETERINARY INSTITUTE, THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK, RAMOT AT TEL-AVIV UNIVERISTY LTD.Inventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20190125808Abstract: The invention provides for methods for treating and preventing colorectal cancer, non-dysplastic serrated polyps, or serrated crypt foci in a subject by administering butyrate producing bacteria, dietary fiber, sodium butyrate, or a combination thereof. The invention also provides methods for detecting, determining and/or diagnosing colorectal cancer, non-dysplastic serrated polyps, or serrated crypt foci in a subject by detection of the level of butyrate producing bacteria in a sample, as well as the alpha diversity, the operational taxonomic units, the level of bacteria Lactobacillales, and the level of CoA and BcoA nucleic acid.Type: ApplicationFiled: March 29, 2017Publication date: May 2, 2019Inventors: W. Ian Lipkin, Brent L. Williams, Mara Couto-Rodriguez
-
Patent number: 10183072Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: GrantFiled: December 15, 2015Date of Patent: January 22, 2019Assignees: KIMRON VETERINARY INSTITUTE, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20180369360Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: ApplicationFiled: August 23, 2018Publication date: December 27, 2018Inventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20170360918Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.Type: ApplicationFiled: December 15, 2015Publication date: December 21, 2017Inventors: W. Ian LIPKIN, Thomas BRIESE, Nischay Mishra, Eran Bacharach, Avi Eldar
-
Publication number: 20170328917Abstract: The invention discloses biomarkers for human autism. The invention provides methods for treating, preventing, and diagnosing human autism and autism-related disorders.Type: ApplicationFiled: December 27, 2016Publication date: November 16, 2017Inventors: Mady HORNIG, W. Ian LIPKIN
-
Publication number: 20160287694Abstract: The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus polypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal.Type: ApplicationFiled: June 14, 2016Publication date: October 6, 2016Inventors: W. Ian Lipkin, Gustavo Palacios, Ruth Toril Kongtorp, Edgar Brun
-
Patent number: 9395356Abstract: The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus poplypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal.Type: GrantFiled: October 4, 2010Date of Patent: July 19, 2016Assignees: The National Veterinary Institute, THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: W. Ian Lipkin, Gustavo Palacios, Ruth T. Kongtorp, Edgar Brun
-
Patent number: 9366667Abstract: The invention is directed to a isolated a Piscine reovirus associated with HSMI in teleosts, and isolated nucleic acids sequences and peptides thereof. The invention also relates to diagnostic antibodies against antigens derived from Piscine reoviruses. In another aspect, the invention relates to iRNAs which target nucleic acid sequences of Piscine reoviruses. In another aspect, the invention is related to methods for detecting the presence or absence of Piscine reoviruses in an animal.Type: GrantFiled: October 4, 2010Date of Patent: June 14, 2016Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE NATIONAL VETERINARY INSTITUTEInventors: W. Ian Lipkin, Gustavo Palacios, Ruth Toril Kongtorp, Edgar Brun
-
Publication number: 20150329909Abstract: The invention discloses biomarkers for human autism. The invention provides methods for treating, preventing, and diagnosing human autism and autism-related disorders.Type: ApplicationFiled: April 20, 2015Publication date: November 19, 2015Inventors: W. Ian LIPKIN, Mady HORNIG, Brent L. WILLIAMS
-
Publication number: 20150219674Abstract: The invention discloses biomarkers for human autism. The invention provides methods for treating, preventing, and diagnosing human autism and autism-related disorders.Type: ApplicationFiled: September 2, 2014Publication date: August 6, 2015Inventors: Mady HORNIG, W. Ian LIPKIN
-
Publication number: 20150183834Abstract: The invention provides a region of strong secondary structure conservation between the C-terminus domain of the envelope glycoprotein of filoviruses and an immunosuppressive domain found in retroviral envelope glycoproteins. The invention provides filoviral peptides and modified derivatives thereof with strong immunosuppressive bioactivity. The invention further provides methods for treatment of autoimmune disorders by administering the immunosuppressive peptide. The invention also provides methods for the identification of therapeutic agents that modulate the immunosuppressive activity of the peptides. Antibodies against the inventive peptides and the modified derivatives thereof are also provided. Furthermore, the invention provides methods for treatment of filoviral infection by administering compositions comprising the antibodies and/or the therapeutic agents that modulate the immunosuppressive activity of the inventive peptides.Type: ApplicationFiled: April 30, 2014Publication date: July 2, 2015Applicant: The Trustees of Columbia University in the City of New YorkInventors: W. Ian LIPKIN, Kavitha YADDANAPUDI, Gustavo PALACIOS
-
Patent number: 9050276Abstract: The invention discloses biomarkers for human autism. The invention provides methods for treating, preventing, and diagnosing human autism and autism-related disorders.Type: GrantFiled: December 16, 2011Date of Patent: June 9, 2015Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: W. Ian Lipkin, Mady Hornig, Brent L. Williams
-
Publication number: 20150093403Abstract: The invention is directed to a isolated a canine circoviruses associated with canine respiratory and gastrointestinal disease, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to antibodies against antigens from canine circoviruses. The invention also relates to iRNAs which target nucleic acid sequences of the canine circovirus. The invention is related to methods for detecting the presence or absence of canine circoviruses in an animal. The invention is also related to immunogenic compositions for inducing an immune response against canine circoviruses in an animal.Type: ApplicationFiled: April 3, 2013Publication date: April 2, 2015Inventors: W. Ian Lipkin, Amit Kapoor, Edward J. Dubovi
-
Publication number: 20140272974Abstract: This invention relates to a novel retroelement, named “Steamer”, found in mollusks, more specifically Mya arenaria, that is associated with haemic neoplasia in these organisms. Haemic neoplasia (HN) is a recognizable leukemic-like disease. The invention provides the retroelement protein, antibodies to the protein, nucleic acids encoding the protein, probes, primer, gene constructs comprising the nucleic acids, host cells comprising the nucleic acids, and methods of using.Type: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Stephen P. Goff, W. Ian Lipkin, Gloria Arriagada, Carol Reinisch, James Sherry, Charles Walker
-
Publication number: 20140128447Abstract: The invention is directed to immunogenic compositions and methods for inducing an immune response against Non-Primate Hepacivirus in an animal. In another aspect, the invention relates to antibodies that bind Non-Primate Hepacivirus polypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing NPHV infection in an animal.Type: ApplicationFiled: May 29, 2013Publication date: May 8, 2014Applicant: The Trustees Of Columbia University In The City Of New YorkInventors: Amit KAPOOR, W. Ian LIPKIN